A Phase 4 interventional study of Lamivudine and Sorbitol in Infection, Human Immunodeficiency Virus, sponsored by ViiV Healthcare. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-15.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Lamivudine (3TC) is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and children. Documented literature elucidates that simultaneous administration of multiple sorbitol-containing products could increase the potential for a significant interaction and may contribute to the lower 3TC exposures.
In this study several sorbitol doses (3.2 gram (g), 10.2 g, and 13.4 g solutions) will be administered with lamivudine to investigate dose dependency and mimic the situation where multiple sorbitol-containing antiretroviral medications may be co-administered with lamivudine. It will be open label, randomized, 4-way crossover (by William's design method) design at a single centre. Randomized participants will receive a single dose of each of four treatments after wash out period of minimum 7 days.
2,096 studies on the registry are indexed under Infections; 364 are open to participants now.
This study's enrollment of 16 is below the median of 113 across 1,304 interventional studies indexed under Infections.
Browse Infections studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Notes:
For purposes of data analysis, Corrected QT interval according to Bazett's formula (QTcB), QTcF, another QT correction formula, or a composite of available values of QTc will be used as specified in the Reporting and Analysis Plan (RAP).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) after overnight fasting. Treatment period will be separated by at least 7 day wash out period.
Drug: Lamivudine
Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 3.2 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period.
Drug: Lamivudine · Drug: Sorbitol
Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 10.2 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period
Drug: Lamivudine · Drug: Sorbitol
Participant will receive single dose of Lamivudine 300 mg (30 ml of 10 mg/ml Oral Solution) + oral solution of Sorbitol 13.4 g after overnight fasting. Treatment period will be separated by at least 7 day wash out period
Drug: Lamivudine · Drug: Sorbitol
It is a clear, colorless to pale yellow solution with the odour of fruit. It will be provided in a 240 mL bottle with the strength of 10 mg/mL Lamivudine 300 mg (30 mL of solution) will be administered orally to the participants
It is a clear, colorless, odourless solution. It will be available in 3 dosage levels viz;. 3.2 g (low dose), 10.2 g (medium dose) and 13.4 g (high dose) sorbitol total dose.
Plasma Lamivudine Area Under the Plasma Concentration Time Curve (AUC) From Time Zero to the Last Quantifiable Time Point (AUC[0-t]), AUC From Time Zero Extrapolated to Infinity (AUC[0-inf]) and AUC From Time Zero to 24 Hours (AUC[0-24])
Serial blood sample were collected at Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, 36 and 48 hours post-dose in each treatment period. AUC was determined using the trapezoidal rule. Analysis of variance (ANOVA), considering treatment and period as fixed effects and participant as random effect, was performed using Mixed Linear Models procedure to compare the plasma lamivudine Pharmacokinetic (PK) parameters.
Time frame: Day 1 to Day 3 in each treatment period
Plasma Lamivudine Maximum Observed Concentration (Cmax), Concentration at 24 Hour (h) Post-dose (C24) and Last Measurable Concentration (Ct)
Serial blood sample were collected at Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, 36 and 48 hours post-dose in each treatment period. Time of the last measurable concentration (t) was 48 hours for all participants and all treatments. ANOVA, considering treatment and period as fixed effects and participant as random effect, was performed using Mixed Linear Models procedure to compare the plasma lamivudine PK parameters.
Time frame: Day 1 to Day 3 in each treatment period
Lamivudine Elimination Half-life in Plasma (t1/2)
Serial blood sample were collected at Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, 36 and 48 hours post-dose in each treatment period. ANOVA, considering treatment and period as fixed effects and participant as random effect, was performed using Mixed Linear Models procedure to compare the plasma lamivudine t1/2.
Time frame: Day 1 to Day 3 in each treatment period
Plasma Lamivudine Apparent Oral Clearance (CL/F)
Serial blood sample were collected at Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, 36 and 48 hours post-dose in each treatment period. ANOVA, considering treatment and period as fixed effects and participant as random effect, was performed using Mixed Linear Models procedure to compare the plasma lamivudine CL/F
Time frame: Day 1 to Day 3 in each treatment period
Time to Observed Maximum Lamivudine Plasma Concentration (Tmax), Time of Last Measurable Plasma Concentration (Tlast) and Absorption Lag Time in Plasma (Tlag)
Serial blood sample were collected at Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, 36 and 48 hours post-dose in each treatment period.
Time frame: Day 1 to Day 3 in each treatment period
Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAE)
An AE is any untoward medical occurrence, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect or event that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition.
Time frame: Up to 5 Weeks
Change From Baseline in Pulse Rate
Change from Baseline for pulse rate was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period.
Time frame: Baseline and up to 5 weeks
Change From Baseline in Body Temperature
Change from Baseline for body temperature was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period.
Time frame: Baseline and up to 5 weeks
Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
Change from Baseline for DBP and SBP was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period.
Time frame: Baseline and up to 5 weeks
Number of Participants With Treatment Emergent Laboratory Abnormality Grade
Division of Acquired immune deficiency syndrome (DAIDS) Table AE grades 1, 2, 3, and 4 of laboratory abnormalities were applied and grade were summarized by treatment and day and were listed by participant, treatment, day, and actual date and time. Treatment emergent grades are defined as any new toxicity grades or the worsened grades compared to Baseline grade. Treatment emergent lab abnormality Grade 1 for aspartate aminotransferase and sodium at follow-up visit are summarized.
Time frame: Up to Week 5
Change From Baseline in Erythrocytes
Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for erythrocytes was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/Period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline.
Time frame: Baseline and up to 5 weeks
Change From Baseline in Hematocrit
Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for hematocrit was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline.
Time frame: Baseline and up to 5 weeks
Change From Baseline in Hemoglobin
Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for hemoglobin was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline.
Time frame: Baseline and up to 5 weeks
Change From Baseline in Mean Corpuscular Hemoglobin (MCH)
Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for MCH was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline.
Time frame: Baseline and up to 5 weeks
Change From Baseline in Mean Corpuscular Volume (MCV)
Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for MCV was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline.
Time frame: Baseline and up to 5 weeks
Change From Baseline in Platelets, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils
Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for platelets, neutrophils, lymphocytes, monocytes, eosinophils, basophils were calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline.
Time frame: Baseline and up to 5 weeks
Change From Baseline in Blood Urea Nitrogen (BUN), Sodium, Potassium, Glucose, Calcium
Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for BUN, sodium, potassium, glucose, calcium were calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline.
Time frame: Baseline and up to 5 weeks
Change From Baseline in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) and Alkaline Phosphates
Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for AST, ALT and alkaline phosphatase were calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline.
Time frame: Baseline and up to 5 weeks
Change From Baseline in Creatinine, Total Bilirubin and Direct Bilirubin
Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for creatinine and direct bilirubin were calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Change from Baseline in total bilirubine was not assessed. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline.
Time frame: Baseline and up to 5 weeks
Change From Baseline in Albumin
Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for albumin was calculated as the post-dose Visit Value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/Period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline.
Time frame: Baseline and up to 5 weeks
| Milestone | Treatment Sequence 1: ADBC | Treatment Sequence 2: BACD | Treatment Sequence 3: CBDA | Treatment Sequence 4: DCAB |
|---|---|---|---|---|
| Started | 4 | 4 | 4 | 4 |
| Completed | 4 | 4 | 4 | 4 |
| Not completed | 0 | 0 | 0 | 0 |
Serial blood sample were collected at Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, 36 and 48 hours post-dose in each treatment period. AUC was determined using the trapezoidal rule. Analysis of variance (ANOVA), considering treatment and period as fixed effects and participant as random effect, was performed using Mixed Linear Models procedure to compare the plasma lamivudine Pharmacokinetic (PK) parameters.
| hour (h)*microgram (mcg)/milliliter (mL) | A: Lamivudine 300 mg | B: Lamivudine 300 mg + Sorbitol 3.2 g | C: Lamivudine 300 mg + Sorbitol 10.2 g | D: Lamivudine 300 mg + Sorbitol 13.4 g |
|---|---|---|---|---|
| AUC (0-inf); n=16, 14, 16, 13 | 13.2 ± 22.3 | 11.3 ± 21.2 | 8.93 ± 22.1 | 8.60 ± 24.1 |
| AUC (0-24) ; n=16, 16, 16, 16 | 12.4 ± 23.6 | 9.96 ± 22.6 | 7.54 ± 23.7 | 6.91 ± 28.9 |
| AUC (0-t) ; n=16, 16, 16, 16 | 12.9 ± 23.0 | 10.6 ± 21.6 | 8.21 ± 22.9 | 7.55 ± 26.8 |
Serial blood sample were collected at Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, 36 and 48 hours post-dose in each treatment period. Time of the last measurable concentration (t) was 48 hours for all participants and all treatments. ANOVA, considering treatment and period as fixed effects and participant as random effect, was performed using Mixed Linear Models procedure to compare the plasma lamivudine PK parameters.
| mcg/mL | A: Lamivudine 300 mg | B: Lamivudine 300 mg + Sorbitol 3.2 g | C: Lamivudine 300 mg + Sorbitol 10.2 g | D: Lamivudine 300 mg + Sorbitol 13.4 g |
|---|---|---|---|---|
| C24 | 0.036 ± 25.1 | 0.036 ± 31.1 | 0.041 ± 21.8 | 0.039 ± 21.6 |
| Ct | 0.013 ± 28.4 | 0.017 ± 26.3 | 0.019 ± 38.7 | 0.018 ± 51.5 |
| Cmax | 3.34 ± 34.9 | 2.42 ± 32.7 | 1.60 ± 27.2 | 1.52 ± 30.9 |
Serial blood sample were collected at Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, 36 and 48 hours post-dose in each treatment period. ANOVA, considering treatment and period as fixed effects and participant as random effect, was performed using Mixed Linear Models procedure to compare the plasma lamivudine t1/2.
| Hour (Hr) | A: Lamivudine 300 mg | B: Lamivudine 300 mg + Sorbitol 3.2 g | C: Lamivudine 300 mg + Sorbitol 10.2 g | D: Lamivudine 300 mg + Sorbitol 13.4 g |
|---|---|---|---|---|
| Lamivudine Elimination Half-life in Plasma (t1/2) | 13.9 ± 20.9 | 19.0 ± 40.6 | 21.2 ± 47.3 | 17.3 ± 48.6 |
Serial blood sample were collected at Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, 36 and 48 hours post-dose in each treatment period. ANOVA, considering treatment and period as fixed effects and participant as random effect, was performed using Mixed Linear Models procedure to compare the plasma lamivudine CL/F
| Liter (L)/hr | A: Lamivudine 300 mg | B: Lamivudine 300 mg + Sorbitol 3.2 g | C: Lamivudine 300 mg + Sorbitol 10.2 g | D: Lamivudine 300 mg + Sorbitol 13.4 g |
|---|---|---|---|---|
| Plasma Lamivudine Apparent Oral Clearance (CL/F) | 22.738 ± 22.3 | 26.621 ± 21.2 | 33.608 ± 22.1 | 34.875 ± 24.1 |
Serial blood sample were collected at Pre-dose; 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, 36 and 48 hours post-dose in each treatment period.
| Hr | A: Lamivudine 300 mg | B: Lamivudine 300 mg + Sorbitol 3.2 g | C: Lamivudine 300 mg + Sorbitol 10.2 g | D: Lamivudine 300 mg + Sorbitol 13.4 g |
|---|---|---|---|---|
| tmax | 0.75 (0.50 to 1.50) | 1.000 (0.50 to 1.50) | 1.00 (0.50 to 2.50) | 1.26 (0.50 to 3.00) |
| tlast | 48.00 (48.00 to 48.22) | 48.00 (47.50 to 48.08) | 48.00 (47.57 to 48.03) | 48.00 (48.00 to 48.07) |
| tlag | 0.000 (0.00 to 0.00) | 0.000 (0.00 to 0.00) | 0.000 (0.00 to 0.00) | 0.000 (0.00 to 0.00) |
An AE is any untoward medical occurrence, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect or event that may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition.
| Participants | A: Lamivudine 300 mg | B: Lamivudine 300 mg + Sorbitol 3.2 g | C: Lamivudine 300 mg + Sorbitol 10.2 g | D: Lamivudine 300 mg + Sorbitol 13.4 g |
|---|---|---|---|---|
| AEs | 1 | 2 | 1 | 1 |
| SAEs | 0 | 0 | 0 | 0 |
Change from Baseline for pulse rate was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period.
| Beats/min | A: Lamivudine 300 mg | B: Lamivudine 300 mg + Sorbitol 3.2 g | C: Lamivudine 300 mg + Sorbitol 10.2 g | D: Lamivudine 300 mg + Sorbitol 13.4 g |
|---|---|---|---|---|
| Day 3; n=15, 16, 16, 16 | 6.5 ± 3.42 | 3.9 ± 14.3 | 6.0 ± 6.86 | 7.4 ± 8.57 |
| Follow up; n=16, 16, 16, 16 | 5.8 ± 6.41 | 5.8 ± 6.41 | 5.8 ± 6.41 | 5.8 ± 6.41 |
Change from Baseline for body temperature was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period.
| Degree centigrade | A: Lamivudine 300 mg | B: Lamivudine 300 mg + Sorbitol 3.2 g | C: Lamivudine 300 mg + Sorbitol 10.2 g | D: Lamivudine 300 mg + Sorbitol 13.4 g |
|---|---|---|---|---|
| Day 3 | 0.03 ± 0.252 | 0.07 ± 0.189 | 0.08 ± 0.183 | -0.03 ± 0.145 |
| Follow up | -0.01 ± 0.365 | -0.01 ± 0.365 | -0.01 ± 0.365 | -0.01 ± 0.365 |
Change from Baseline for DBP and SBP was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period.
| millimeter of mercury (mmHg) | A: Lamivudine 300 mg | B: Lamivudine 300 mg + Sorbitol 3.2 g | C: Lamivudine 300 mg + Sorbitol 10.2 g | D: Lamivudine 300 mg + Sorbitol 13.4 g |
|---|---|---|---|---|
| DBP, Day 3; n=15, 16, 16, 16 | 5.1 ± 6.41 | 4.5 ± 4.13 | 2.1 ± 7.46 | 5.6 ± 4.87 |
| DBP, Follow up; n=16, 16, 16, 16 | 4.6 ± 6.54 | 4.6 ± 6.54 | 4.6 ± 6.54 | 4.6 ± 6.54 |
| SBP, Day 3; n=15, 16, 16, 16 | 3.6 ± 9.84 | 3.1 ± 8.01 | 5.1 ± 7.19 | 5.3 ± 7.38 |
| SBP, Follow up; n=16, 16, 16, 16 | 7.4 ± 7.78 | 7.4 ± 7.78 | 7.4 ± 7.78 | 7.4 ± 7.78 |
Division of Acquired immune deficiency syndrome (DAIDS) Table AE grades 1, 2, 3, and 4 of laboratory abnormalities were applied and grade were summarized by treatment and day and were listed by participant, treatment, day, and actual date and time. Treatment emergent grades are defined as any new toxicity grades or the worsened grades compared to Baseline grade. Treatment emergent lab abnormality Grade 1 for aspartate aminotransferase and sodium at follow-up visit are summarized.
| Participants | A: Lamivudine 300 mg | B: Lamivudine 300 mg + Sorbitol 3.2 g | C: Lamivudine 300 mg + Sorbitol 10.2 g | D: Lamivudine 300 mg + Sorbitol 13.4 g |
|---|---|---|---|---|
| Aspartate Aminotransferase | 1 | 1 | 1 | 1 |
| Sodium | 1 | 1 | 1 | 1 |
Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for erythrocytes was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/Period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline.
| 10^12 cells/L | A: Lamivudine 300 mg | B: Lamivudine 300 mg + Sorbitol 3.2 g | C: Lamivudine 300 mg + Sorbitol 10.2 g | D: Lamivudine 300 mg + Sorbitol 13.4 g |
|---|---|---|---|---|
| Day 3 | 0.351 ± 0.298 | 0.389 ± 0.200 | 0.339 ± 0.257 | 0.380 ± 0.243 |
| Follow up | 0.142 ± 0.148 | 0.142 ± 0.148 | 0.142 ± 0.148 | 0.142 ± 0.148 |
Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for hematocrit was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline.
| Fraction of 1 | A: Lamivudine 300 mg | B: Lamivudine 300 mg + Sorbitol 3.2 g | C: Lamivudine 300 mg + Sorbitol 10.2 g | D: Lamivudine 300 mg + Sorbitol 13.4 g |
|---|---|---|---|---|
| Day 3 | 0.0338 ± 0.02429 | 0.0378 ± 0.02206 | 0.0308 ± 0.01993 | 0.0353 ± 0.01892 |
| Follow up | 0.0091 ± 0.01254 | 0.0091 ± 0.01254 | 0.0091 ± 0.01254 | 0.0091 ± 0.01254 |
Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for hemoglobin was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline.
| G/L | A: Lamivudine 300 mg | B: Lamivudine 300 mg + Sorbitol 3.2 g | C: Lamivudine 300 mg + Sorbitol 10.2 g | D: Lamivudine 300 mg + Sorbitol 13.4 g |
|---|---|---|---|---|
| Day 3 | 10.1 ± 8.05 | 10.9 ± 5.26 | 9.8 ± 6.44 | 9.9 ± 5.83 |
| Follow up | 3.4 ± 4.57 | 3.4 ± 4.57 | 3.4 ± 4.57 | 3.4 ± 4.57 |
Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for MCH was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline.
| Picogram | A: Lamivudine 300 mg | B: Lamivudine 300 mg + Sorbitol 3.2 g | C: Lamivudine 300 mg + Sorbitol 10.2 g | D: Lamivudine 300 mg + Sorbitol 13.4 g |
|---|---|---|---|---|
| Day 3 | 0.02 ± 0.500 | -0.03 ± 0.419 | 0.06 ± 0.403 | -0.24 ± 0.622 |
| Follow up | -0.14 ± 0.567 | -0.14 ± 0.567 | -0.14 ± 0.567 | -0.14 ± 0.567 |
Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for MCV was calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline.
| Femtoliter | A: Lamivudine 300 mg | B: Lamivudine 300 mg + Sorbitol 3.2 g | C: Lamivudine 300 mg + Sorbitol 10.2 g | D: Lamivudine 300 mg + Sorbitol 13.4 g |
|---|---|---|---|---|
| Day 3 | 0.71 ± 1.95 | 0.63 ± 1.89 | 0.35 ± 2.06 | 0.44 ± 1.54 |
| Follow up | -0.77 ± 1.55 | -0.77 ± 1.55 | -0.77 ± 1.55 | -0.77 ± 1.55 |
Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for platelets, neutrophils, lymphocytes, monocytes, eosinophils, basophils were calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline.
| 10^9 cells/L | A: Lamivudine 300 mg | B: Lamivudine 300 mg + Sorbitol 3.2 g | C: Lamivudine 300 mg + Sorbitol 10.2 g | D: Lamivudine 300 mg + Sorbitol 13.4 g |
|---|---|---|---|---|
| Platelets, Day 3 | 19.2 ± 20.69 | 13.9 ± 15.75 | 13.8 ± 20.92 | 6.1 ± 24.65 |
| Platelets, Follow up | 2.3 ± 19.36 | 2.3 ± 19.36 | 2.3 ± 19.36 | 2.3 ± 19.36 |
| Neutrophils, Day 3 | 0.35 ± 0.612 | 0.42 ± 0.733 | 0.53 ± 0.603 | 0.31 ± 0.979 |
| Neutrophils, Follow up | -0.12 ± 0.717 | -0.12 ± 0.717 | -0.12 ± 0.717 | -0.12 ± 0.717 |
| Lymphocytes, Day 3 | 0.10 ± 0.432 | 0.17 ± 0.338 | 0.00 ± 0.446 | -0.03 ± 0.466 |
| Lymphocytes, Follow up | -0.08 ± 0.371 | -0.08 ± 0.371 | -0.08 ± 0.371 | -0.08 ± 0.371 |
| Monocytes, Day 3 | 0.01 ± 0.085 | 0.03 ± 0.060 | -0.02 ± 0.122 | -0.01 ± 0.112 |
| Monocytes, Follow up | -0.08 ± 0.134 | -0.08 ± 0.134 | -0.08 ± 0.134 | -0.08 ± 0.134 |
| Eosinophils, Day 3 | -0.03 ± 0.070 | -0.02 ± 0.075 | -0.04 ± 0.062 | -0.03 ± 0.070 |
| Eosinophils, Follow up | -0.01 ± 0.068 | -0.01 ± 0.068 | -0.01 ± 0.068 | -0.01 ± 0.068 |
| Basophils, Day 3 | -0.01 ± 0.025 | 0.00 ± 0.000 | -0.01 ± 0.025 | 0.00 ± 0.037 |
| Basophils, Follow up | -0.01 ± 0.025 | -0.01 ± 0.025 | -0.01 ± 0.025 | -0.01 ± 0.025 |
Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for BUN, sodium, potassium, glucose, calcium were calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline.
| millimole (mmol)/L | A: Lamivudine 300 mg | B: Lamivudine 300 mg + Sorbitol 3.2 g | C: Lamivudine 300 mg + Sorbitol 10.2 g | D: Lamivudine 300 mg + Sorbitol 13.4 g |
|---|---|---|---|---|
| BUN, Day 3 | -0.0892 ± 1.08675 | -0.5578 ± 0.93974 | 0.0223 ± 1.05476 | 0.0446 ± 1.38496 |
| BUN, Follow up | -0.4909 ± 1.00870 | -0.4909 ± 1.00870 | -0.4909 ± 1.00870 | -0.4909 ± 1.00870 |
| Sodium, Day 3 | -2.4 ± 1.71 | -1.2 ± 1.42 | -2.6 ± 1.59 | -2.0 ± 1.63 |
| Sodium, Follow up | -0.1 ± 2.03 | -0.1 ± 2.03 | -0.1 ± 2.03 | -0.1 ± 2.03 |
| Potassium, Day 3 | 0.06 ± 0.418 | 0.09 ± 0.481 | 0.19 ± 0.382 | 0.06 ± 0.386 |
| Potassium, Follow up | 0.02 ± 0.387 | 0.02 ± 0.387 | 0.02 ± 0.387 | 0.02 ± 0.387 |
| Glucose, Day 3 | -0.05897 ± 0.496601 | 0.05550 ± 0.342125 | 0.01388 ± 0.342425 | -0.03122 ± 0.657300 |
| Glucose, Follow up | 0.33994 ± 0.546377 | 0.33994 ± 0.546377 | 0.33994 ± 0.546377 | 0.33994 ± 0.546377 |
| Calcium Day 3 | 0.0906 ± 0.11614 | 0.1141 ± 0.08214 | 0.1141 ± 0.07744 | 0.0875 ± 0.07583 |
| Calcium, Follow up | 0.0328 ± 0.05379 | 0.0328 ± 0.05379 | 0.0328 ± 0.05379 | 0.0328 ± 0.05379 |
Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for AST, ALT and alkaline phosphatase were calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline.
| Unit (U)/L | A: Lamivudine 300 mg | B: Lamivudine 300 mg + Sorbitol 3.2 g | C: Lamivudine 300 mg + Sorbitol 10.2 g | D: Lamivudine 300 mg + Sorbitol 13.4 g |
|---|---|---|---|---|
| AST, Day 3 | -3.1 ± 4.84 | -3.5 ± 3.67 | -2.3 ± 2.44 | -19.1 ± 68.13 |
| AST, Follow up | 1.1 ± 15.86 | 1.1 ± 15.86 | 1.1 ± 15.86 | 1.1 ± 15.86 |
| ALT, Day 3 | -2.2 ± 5.78 | -2.7 ± 4.16 | -2.2 ± 2.59 | -2.5 ± 7.05 |
| ALT, Follow up | 0.4 ± 8.97 | 0.4 ± 8.97 | 0.4 ± 8.97 | 0.4 ± 8.97 |
| Alkaline phosphatatse, Day 3 | -0.4 ± 7.96 | 1.1 ± 6.24 | 1.5 ± 8.45 | -0.2 ± 7.37 |
| Alkaline phosphatase, Follow up | 1.2 ± 7.01 | 1.2 ± 7.01 | 1.2 ± 7.01 | 1.2 ± 7.01 |
Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for creatinine and direct bilirubin were calculated as the post-dose visit value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/period. Change from Baseline in total bilirubine was not assessed. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline.
| micromole (umol)/L | A: Lamivudine 300 mg | B: Lamivudine 300 mg + Sorbitol 3.2 g | C: Lamivudine 300 mg + Sorbitol 10.2 g | D: Lamivudine 300 mg + Sorbitol 13.4 g |
|---|---|---|---|---|
| Creatinine, Day 3 | 3.86759 ± 9.112270 | 2.21005 ± 6.847589 | 4.42010 ± 7.217993 | 0.55251 ± 6.011986 |
| Creatinine, Follow up | 0.00000 ± 7.217993 | 0.00000 ± 7.217993 | 0.00000 ± 7.217993 | 0.00000 ± 7.217993 |
| Direct bilirubin, Day 3 | 0.641 ± 0.8550 | 0.107 ± 1.3200 | 0.107 ± 0.7567 | 0.321 ± 1.1202 |
| Direct bilirubin, Follow up | 0.107 ± 1.4602 | 0.107 ± 1.4602 | 0.107 ± 1.4602 | 0.107 ± 1.4602 |
Blood samples were collected at Day -1, Day 3 of every treatment period and at follow-up. Change from Baseline for albumin was calculated as the post-dose Visit Value minus the value at Baseline, at Day 3 and Follow-up. Baseline value used in the analysis was the latest pre-dose values on Day 1 of each treatment/Period. Day -1 presented the Baseline absolute values; Day 3 and Follow-Up presented the changes from Baseline.
| G//L | A: Lamivudine 300 mg | B: Lamivudine 300 mg + Sorbitol 3.2 g | C: Lamivudine 300 mg + Sorbitol 10.2 g | D: Lamivudine 300 mg + Sorbitol 13.4 g |
|---|---|---|---|---|
| Day 3 | 1.8 ± 2.43 | 2.3 ± 1.58 | 2.1 ± 2.38 | 2.1 ± 2.09 |
| Follow up | 0.6 ± 1.63 | 0.6 ± 1.63 | 0.6 ± 1.63 | 0.6 ± 1.63 |
Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of study medication until follow-up (up to 5 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| A: Lamivudine 300 mg | — | 0/16 (0%) | 1/16 (6.3%) |
| B: Lamivudine 300 mg + Sorbitol 3.2 g | — | 0/16 (0%) | 2/16 (12.5%) |
| C: Lamivudine 300 mg + Sorbitol 10.2 g | — | 0/16 (0%) | 1/16 (6.3%) |
| D: Lamivudine 300 mg + Sorbitol 13.4 g | — | 0/16 (0%) | 1/16 (6.3%) |
| Event | A: Lamivudine 300 mg | B: Lamivudine 300 mg + Sorbitol 3.2 g | C: Lamivudine 300 mg + Sorbitol 10.2 g | D: Lamivudine 300 mg + Sorbitol 13.4 g |
|---|---|---|---|---|
| GastroenteritisInfections and infestations | 0/16 | 1/16 | 0/16 | 0/16 |
| Vaginal infectionInfections and infestations | 0/16 | 0/16 | 0/16 | 1/16 |
| Vessel puncture site painGeneral disorders | 0/16 | 1/16 | 0/16 | 0/16 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/16 | 0/16 | 0/16 | 0/16 |
| DizzinessNervous system disorders | 0/16 | 0/16 | 1/16 | 0/16 |
| Age, Continuous(Years) | All Treatment Groups Combined |
|---|---|
| Mean | 40.6 ± 12.30 |
| Sex: Female, Male(Participants) | All Treatment Groups Combined |
|---|---|
| Female | 2 |
| Male | 14 |
| Race/Ethnicity, Customized(Participants) | All Treatment Groups Combined |
|---|---|
| African American/African Heritage | 6 |
| White - White/Caucasian/European Heritage | 10 |
The record gives a start of Jan 2016, a primary completion of Mar 2016 and a completion of Mar 2016. It does not say whether these dates are actual or estimated.
Results were first posted in May 2017, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lamivudine · Sorbitol